The Latest Cardiac and Vascular News
New pacemakers offer 40% more battery life,1 extend Medtronic legacy of pacing leadership DUBLIN – May 1, 2023 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its Micra™ AV2 and Micra™ VR2, the next […]
Presented at Charing Cross, 10-Year Clinical Data from Global ENGAGE OUS Registry Support Endurant Stent Graft System’s AAA Market-Leading Position Worldwide Medtronic today announced its EndurantTM abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability through proven outcomes in a real-world setting1. The 10-year Endurant Stent Graft Natural Selection […]
12-month results reinforce versatility and durability for the treatment of paroxysmal and persistent AFib with the first-of-its-kind pulsed field ablation, radiofrequency, and high density mapping Sphere-9™ Catheter Medtronic today announced the 12-month findings that supported the Affera™ Mapping and Ablation System CE Mark, demonstrating that the Sphere-9™ Catheter can successfully […]
DUBLIN, March 23, 2023 /PRNewswire/ — Medtronic plc (the “Company”) (NYSE: MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. (“Medtronic Luxco”), has priced an offering (the “Offering”) of $1,000,000,000 principal amount of 4.25% senior notes due 2028 and $1,000,000,000 principal amount of 4.50% senior notes due 2033 (collectively, the “Notes”). All of Medtronic Luxco’s obligations […]
First of its kind, all-in-one Sphere-9™ Catheter with pulsed field ablation, radiofrequency, and high density mapping integrated with intuitive mapping and navigation platform DUBLIN, March 15, 2023 /PRNewswire/ — Medtronic (NYSE:MDT) announced today that it has received CE (Conformité Européenne) Mark for the Affera™ Mapping and Ablation System, which includes the Sphere-9™ […]
ACC.23/WCC Late-Breaking Clinical Trial: Evolut™ is only TAVR to show excellent outcomes in low-risk patients at 3 years Medtronic today announced three-year data from the Evolut Low Risk Trial, demonstrating the Medtronic EvolutTM transcatheter aortic valve replacement (TAVR) System had numerically better clinical outcomes and significantly better hemodynamic valve performance than […]
ACC.23/WCC late-breaking data: PULSED AF, one of the most rigorously executed PFA clinical studies to date, exceeds safety and efficacy performance goals in the treatment of paroxysmal and persistent atrial fibrillation DUBLIN and NEW ORLEANS, March 6, 2023 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its PulseSelect™ Pulsed Field […]
DUBLIN, March 2, 2023 /PRNewswire/ — The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 2, 2023, approved the fiscal year 2023 fourth quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May […]
Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios DUBLIN, Feb. 21, 2023 /PRNewswire/ — Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2023, which ended January 27, 2023. Key Highlights Revenue of $7.7 billion was flat as reported and increased 4.1% organic, […]
EV-ICD defibrillation lead placed outside of heart and veins, preserving vasculature DUBLIN, Feb. 17, 2023 /PRNewswire/ — Medtronic plc (NYSE:MDT) has received CE (Conformité Européenne) Mark for the Aurora EV-ICD™ MRI SureScan™ (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV™ MRI SureScan™ defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden […]
